QC
GILD icon

Quadrature Capital’s Gilead Sciences GILD Stock Holding History

Quadrature Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.73M Sell
13,731
-43,197
-76% -$5.69M 0.01% 553
2026
Q1 		$7.93M Buy
+56,928
New +$7.97M 0.09% 175

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Quadrature Capital's GILD Position: Q2 2026 in Review

Quadrature Capital reduced its Gilead Sciences (GILD) stake by 76% in Q2 2026, selling an estimated $5.69M and leaving 13,731 shares worth $1.73M. The position accounts for 0.01% of the portfolio, ranked #553.

Quadrature Capital first reported a position in GILD in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.93M in Q1 2026. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Quadrature Capital held 13,731 shares of Gilead Sciences worth $1.73M as of Q2 2026.
  • Quadrature Capital sold 43,197 Gilead Sciences shares in Q2 2026, an estimated $5.69M.
  • Gilead Sciences made up 0.01% of Quadrature Capital's portfolio in Q2 2026, its #553 holding.
  • Quadrature Capital first reported a position in Gilead Sciences in Q1 2026 and has held it in 2 quarters since.
  • Quadrature Capital's Gilead Sciences position peaked at $7.93M in Q1 2026.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.